Drug Trial Radar · NCT07682558
Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
318
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Nov 2029
Study completion Nov 2029
Sponsor
- Lead sponsor
- University Hospital, Basel, SwitzerlandAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Swiss GO Trial Group; Swiss National Science Foundation
- First posted
- Jul 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators investigate the efficacy of non-opioid analgesics compared to placebo together with opioid therapy for cancer pain management.
Conditions
- Cancer Pain
- Cancer Palliative Care
Interventions
MetamizoleDrug
Metamizole 4 g/d as: 2 capsules of 500 mg Metamizole each (1000 mg) taken 4 x daily orally.
IbuprofenDrug
Ibuprofen 1.2 g/d as: 2 capsules of 150 mg Ibuprofen each (300 mg) taken 4 x daily orally
PlaceboOther
Placebo 0 g/d as: 2 capsules containing inactive substance (mannitol) taken 4 x daily orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in cancer painTime frame: up to 5 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Basel
Basel, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.